TABLE 1.
Organism | Genotype | MLSTh | MIC (mg/liter) |
|||||
---|---|---|---|---|---|---|---|---|
Ceftazidime | Cefepime | Ceftolozane-tazobactam | Ceftazidime-avibactam | Imipenem | Meropenem | |||
PSA INT-7-65 | blaOXA-56,ablaOXA-50b (OXA-904 by BLAST), blaOXA-392c, blaPAO (blaPDC-117) | 260 | 4d | 32f | 4 | 4 | 16 | 32 |
PSA INT-9-5 | blaOXA-35,ablaOXA-488,bblaPAO (blaPDC-35) | 235 | 4d | 32f | 2 | 2 | 32 | >64 |
PSA INT-9-11 | blaOXA-10,ablaOXA-488,bblaPAO (blaPDC-35) | 235 | 8e | 64g | 8 | 4 | 16 | 64 |
blaOXA-10-like family. For PSA INT-7-65, blaOXA-56 could not be distinguished from blaOXA-101.
blaOXA-50-like family. For PSA INT-7-65, blaOXA-50 could not be distinguished from blaOXA-396 or blaOXA-494.
blaOXA-1-like family.
Ceftazidime 2 g q8h 2-h infusion HSR, 100% fT > MIC (9).
Ceftazidime 2 g q8h 2-h infusion HSR, 87% fT > MIC (9).
Cefepime 2 g q8h 2-h infusion HSR, 38% fT > MIC; cefepime 1 g q8h 2-h infusion HSR, 8% fT > MIC (10).
Cefepime 2 g q8h 2-h infusion HSR, 8% fT > MIC; cefepime 1 g q8h 2-h infusion HSR, 0% fT > MIC (10).
MLST, multilocus sequence type.